Oliver Schönborn-Kellenberger earned his MSc in Mathematics from Georg August University in Göttingen. He began his career as a statistician at PRA, a CRO, in 2004 before joining Novartis Pharma AG in 2006. In 2008, he transitioned to Novartis Oncology, where he took on responsibility for a major compound in early development. In 2012, he pursued a new opportunity at ImClone International, further expanding his experience in oncology drug development. The following year, in 2013, he embarked on an entrepreneurial journey, leveraging his expertise to drive innovation in the field.

Throughout his career, he has played a pivotal role in the design, execution, and reporting of numerous fully Bayesian single-agent and combination escalation trials, as well as Bayesian Phase II studies. His expertise spans a broad range of statistical methodologies, with a strong focus on Bayesian adaptive designs, dose-finding strategies—including those aligned with FDA's Project Optimus—and predictive modeling to optimize clinical development strategies.

With extensive experience in oncology and hematology, he has contributed to the approval, conduct, and reporting of over 50 fully Bayesian Phase 1/2 studies. His work has encompassed a diverse range of cancer indications, including solid tumors, Hodgkin's and non-Hodgkin's lymphoma, multiple myeloma, acute myeloid leukemia (AML), glioblastoma, prostate cancer, and vaccine development, among others.

Michael Kruse holds a degree as economist (Diplom Volkswirt) and studied in Hamburg and Liverpool. He joined Cogitars GmbH in 2015. Michael is specialised in building up professional business structures which will be helpful in Cogitars' growth process over the next years. Since Michael worked in Berlin as a consultant for companies in the health sector, he has a deep understanding of both pharmaceutical as well as medtec companies and their business models.

Miguel is a former physician turned statistician. He holds a MSc in Biostatistics and PhD in Bayesian Statistics applied to epidemiology from Imperial College London. Miguel joined Cogitars in 2021 and, in 2023, opened Cogitars UK, the United Kingdom branch of Cogitars.

In his 10+ years experience in pharma, biotech and medical devices, Miguel has worked as a consultant with UCB, Astrazeneca and the WHO, among others. He has designed and led several Bayesian trials, including the development of novel Bayesian methodology.